David Hartig, MD
Family Medicine · Hunt Valley, MDNPI 1093797995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,004 and has fallen 98.5% since, to $30 in 2023.
Across 186 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$322
- Amgen$277
- AstraZeneca$262
- Novo Nordisk$245
- Lilly USA, LLC$208
- Pfizer$202
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,692100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $322 |
| Amgen(2 entities) | 17 | $277 |
| AstraZeneca | 20 | $262 |
| Novo Nordisk | 18 | $245 |
| Lilly USA, LLC | 18 | $208 |
| Pfizer | 17 | $202 |
| Boehringer Ingelheim | 13 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Astellas Pharma US Inc | 6 | $109 |
| Neos Therapeutics, LP | 5 | $105 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Amarin Pharma, Inc. | 4 | $78 |
| Merck | 6 | $75 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $32 |
| Merz North America, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Therapeuticsmd, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$2,700 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $149,905 |
| TrulicityDulaglutide | 82 | $125,398 |
| XareltoRivaroxaban | 87 | $92,069 |
| JardianceEmpagliflozin | 63 | $73,481 |
| EliquisApixaban | 54 | $57,341 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $20,585 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $20,322 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $17,675 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,806 |
| Dexlansoprazole DrDexlansoprazole | 32 | $11,228 |
| SynthroidLevothyroxine Sodium | 102 | $8,792 |
| VascepaIcosapent Ethyl | 11 | $7,182 |
| Rosuvastatin Calcium | 343 | $6,580 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 26 | $6,078 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $245 | $149,90575 claims |
| Lilly USA, LLCTrulicity | $208 | $125,39882 claims |
| Johnson & JohnsonXarelto | $32 | $92,06987 claims |
| Boehringer IngelheimJardiance | $196 | $73,48163 claims |
| PfizerEliquis, Dilantin | $202 | $60,34865 claims |
| MerckJanumet Xr | $75 | $20,58513 claims |
| AbbVieSynthroid | $322 | $8,792102 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $151 | $5,65012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Hunt Valley
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.